Last updated: February 14, 2026
Overview
NDC 68084-0988 corresponds to Zirgan (ganciclovir ophthalmic gel 0.15%), used primarily for the treatment of ocular herpes simplex virus infections. The drug's market landscape involves ophthalmologists, infectious disease specialists, and healthcare providers managing viral ocular infections. With a focus on stability in patent protections, competitive generics, and pricing strategies, this analysis examines current market trends and generates price projections through 2028.
Market Size and Key Drivers
- The global ophthalmic antiviral market was valued at approximately $400 million in 2022, with sustained growth driven by rising incidence of herpetic keratitis.
- Herpetic eye disease affects an estimated 1.7 million individuals annually worldwide, with U.S. incidence rates around 1.8 cases per 100,000 population per year.
- In the U.S., Zirgan holds approximately 60% of the herpes keratitis treatment market, with sales estimated at $180 million in 2022.
Market Dynamics
- Competitive Landscape: Ganciclovir ophthalmic gel faces competition mainly from compounded formulations and off-label usages of systemic antivirals.
- Patent and Exclusivity: UCB Pharma, the original patent holder, lost exclusivity in the U.S. in 2019, enabling generic entrants.
- Regulatory Pathway: The first generic approval occurred in late 2019, with multiple approvals following.
- Physician Adoption: Clinicians prefer Zirgan based on clinical experience, though cost considerations favor generics.
- Pricing Trends: The brand's average wholesale price (AWP) stabilized at approximately $750 for a 3-gram tube. Generics initially entered at 30-50% lower prices.
Historical Pricing Data
| Year |
Zirgan (Brand) Price |
Generic Entry Price |
Market Share (Zirgan) |
| 2019 |
$750 |
$400 |
70% |
| 2020 |
$730 |
$340 |
65% |
| 2021 |
$720 |
$320 |
60% |
| 2022 |
$710 |
$300 |
60% |
Price Projection Assumptions
- Patent exclusivity remains effectively open due to multiple generics.
- Market growth rate stabilizes at roughly 2% annually, influenced by increased awareness and diagnosis.
- Pricing pressure from competitive generics persists, but clinicians’ preference sustains higher brand pricing margins.
Price Forecast (2023-2028)
| Year |
Estimated Zirgan Price |
Estimated Generic Price |
Market Share (Zirgan) |
| 2023 |
$700 |
$250 |
55% |
| 2024 |
$680 |
$230 |
50% |
| 2025 |
$670 |
$210 |
45% |
| 2026 |
$660 |
$200 |
40% |
| 2027 |
$650 |
$195 |
35% |
| 2028 |
$640 |
$190 |
30% |
Key Factors Influencing Price Movements
- Generic Competition: Increasing number of generic manufacturers will exert downward pressure.
- Regulatory Incentives: Potential biosimilar or reformulation approvals could influence margins.
- Market Penetration: Growing awareness may sustain a higher market share for the brand through brand loyalty.
- Reimbursement Policies: Payer push for lower-cost generics will accelerate price declines.
Conclusion
The price of Zirgan is forecasted to decline modestly over the next five years, with a gradual erosion of the brand's market share due to generic competition. However, brand pricing may remain relatively stable compared to initial post-patent loss declines, given established clinician preferences and limited generics with differentiated formulations.
Key Takeaways
- Zirgan's market experienced expansion until patent loss in 2019, leading to generic entry.
- Prices declined from approximately $750 in 2019 to about $640 forecasted for 2028.
- Market share shifts gradually toward generics, but brand loyalty sustains a margin.
- Pricing pressure from generics will continue, with brand prices (\sim) 12% lower over five years.
- The most significant market driver remains the incidence of herpetic keratitis and ophthalmologists' prescribing habits.
FAQs
-
How does patent expiry affect Zirgan's market price?
Patent expiry opened the market to generics, leading to a significant reduction in prices and increased competition.
-
What is the expected impact of new generics on pricing?
Additional generic approvals will likely push prices downward, especially if multiple players enter simultaneously.
-
Are there current regulatory barriers to generic entry?
No, multiple generics have already been approved, though regulatory delays for new entrants are still possible.
-
What role does physician preference play in market stability?
Clinician familiarity with Zirgan sustains a higher brand share despite price reductions.
-
Could reformulation or alternative delivery methods affect the market?
Yes, reformulations or biosimilars could alter price dynamics and market share over the next decade.
References
- Markets and Markets. "Ophthalmic Antiviral Market." 2022.
- U.S. FDA. "ANDA Approvals for Ganciclovir Ophthalmic Gel," 2019.
- IQVIA. "Pharmaceutical Pricing Data," 2022.
- Pharma Intelligence. "Ophthalmic Drug Market Analysis," 2023.
- CDC. "Herpetic Eye Disease Incidence," 2022.
